Recent Submissions
Ponatinib delays the growth of solid tumours by remodelling immunosuppressive tumour microenvironment through the inhibition of induced PD-L1 expression
See
HDAC5 modulates SATB1 transcriptional activity to promote lung adenocarcinoma
See
Repurposing Ponatinib as a PD-L1 Inhibitor Revealed by Drug Repurposing Screening and Validation by In Vitro and In Vivo Experiments
See
SIRT6 deacetylates PKM2 to suppress its nuclear localization and oncogenic functions
See
Cyclin F-Dependent Degradation of RBPJ Inhibits IDH1R132H-Mediated Tumorigenesis
See
Browse